If you have been reading about HGF/c-Met and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-27. Numbers and descriptions here follow the published literature rather than marketing material.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Identity and purity of dihexa samples are typically assessed with high-performance liquid chromatography and mass spectrometry. These methods can confirm molecular mass and estimate the presence of impurities. However, a certificate of analysis from a supplier is not a guarantee of independent testing. Researchers often require in-house verification before using a peptide in experiments. For solid samples, appearance, solubility, and chromatographic profile provide additional checks. Nuclear magnetic resonance may be used for structural confirmation when available.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
| Property | Value | Notes |
|---|---|---|
| Typical analytical method | LC-MS and HPLC | Used for identity and purity assessment. |
| Purity specification | ≥95% or ≥98% in research grades | Actual purity depends on supplier and batch. |
| Stability in solution | Limited; prepare fresh | Aqueous and organic stocks may degrade over time. |
| Recommended storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles. |
| Regulatory status | Not approved for human use | Sold as a research chemical in some regions. |
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
== Discovery == Collagen XXIII was first identified and isolated from rat prostate carcinoma cells by Jacqueline Banyard, Lere Bao and Bruce R. Zetter in 2003. They also identified this protein in human tissue. They concluded that at the nucleotide level, human and rat collagen XXIII alpha 1 show 76% identity. Furthermore, cellular localization of collagen XXIII was determined by immunofluorescence staining, using an antibody that recognizes the carboxyl terminus of the protein. It was demonstrated that the carboxyl terminus of collagen XXIII is present on the cell surface.
==== Cold fusion ==== The table below provides cross-sections and excitation energies for cold fusion reactions producing nobelium isotopes directly. Data in bold represents maxima derived from excitation function measurements. + represents an observed exit channel.
The party that were ordered last evening set out early this morning. the weather was fair and could wind N. W. about five o'clock this evening one of the wives of Charbono was delivered of a fine boy. It is worthy of remark that this was the first child which this woman had boarn and as is common in such cases her labour was tedious and the pain violent; Mr. Jessome informed me that he had freequently administered a small portion of the rattle of the rattle-snake, which he assured me had never failed to produce the desired effect, that of hastening the birth of the child; having the rattle of a snake by me I gave it to him and he administered two rings of it to the woman broken in small pieces with the fingers and added to a small quantity of water. Whether this medicine was truly the cause or not I shall not undertake to determine, but I was informed that she had not taken it more than ten minutes before she brought forth perhaps this remedy may be worthy of future experiments, but I must confess that I want faith as to it's efficacy.
Tibet subsequently expanded the war, attempting to capture parts of southern Qinghai province. In March 1932 their force invaded Qinghai, but was defeated. Liu, in cooperation with the Ma clique army of Ma Bufang, sent out a brigade under Yu Songling (余松琳) to attack the Tibetan troops in Garze and Xinlong, eventually re-occupying them and all territories east of the Jinsha River. By then, there were around 8,000 troops from Liu's 24th Army in Kham. The Dalai Lama once again appealed to Nanjing, but Liu ignored the central government's calls for peace and began preparations for an attack on Chamdo over the summer of 1932. This planned offensive did not occur because a ceasefire was called in October. The Kamtok (Guangtou) Agreement set the border between the two parties on the Jinsha river. A 1933 analysis of the situation by Deng Shiyi, one of Liu's subordinates, claimed that the war with Tibet was ended only because continuing the offensive could strain relations with Great Britain; however historians Kim Hee-shin and Leibold generally believe that it is far likelier the conflict ended because Liu was facing a far more pressing priority: the war in Sichuan.
Sources: en.wikipedia.org
In quantum mechanics and quantum field theory, the vacuum is defined as the state (that is, the solution to the equations of the theory) with the lowest possible energy (the ground state of the Hilbert space). In quantum electrodynamics this vacuum is referred to as 'QED vacuum' to distinguish it from the vacuum of quantum chromodynamics, denoted as QCD vacuum. QED vacuum is a state with no matter particles (hence the name), and no photons. As described above, this state is impossible to achieve experimentally. (Even if every matter particle could somehow be removed from a volume, it would be impossible to eliminate all the blackbody photons.) Nonetheless, it provides a good model for realizable vacuum, and agrees with a number of experimental observations as described next. QED vacuum has interesting and complex properties. In QED vacuum, the electric and magnetic fields have zero average values, but their variances are not zero. As a result, QED vacuum contains vacuum fluctuations (virtual particles that hop into and out of existence), and a finite energy called vacuum energy. Vacuum fluctuations are an essential and ubiquitous part of quantum field theory. Some experimentally verified effects of vacuum fluctuations include spontaneous emission and the Lamb shift. Coulomb's law and the electric potential in vacuum near an electric charge are modified. Theoretically, in QCD multiple vacuum states can coexist. The starting and ending of cosmological inflation is thought to have arisen from transitions between different vacuum states.
The Greenspan lab was also involved in studies showing that mutations that affect the protease BMP-1 underlie some cases of osteogenesis imperfecta (brittle bone disease), and showing molecular mechanisms involved.
The Zeisel determination for methoxyl group analysis indicated two methoxyl groups per molecule. John Elix and Brian Ferguson proposed a method for the total synthesis of confluentic acid in 1978. The synthesis began with the direct condensation of suitably substituted aromatic carboxylic acids and phenols, using dicyclohexylcarbodiimide. Key precursors involved were specially prepared benzoic acids, with protective measures for reactive groups. The process included steps like bromination, alkylation, and the strategic use of protecting groups for the phenol and carboxyl functionalities. The synthesis culminated in the removal of protecting groups and hydrogenolysis over palladised carbon to yield the desired depsides including confluentic acid. In 1993, G. Fegie and colleagues introduced a standardised high-performance liquid chromatographic method that enabled the separation and detection of hundreds of lichen products, confluentic acid included.
Sources: en.wikipedia.org
== Clinical significance == Selenium is a vital nutrient in animals, including humans. About 25 different selenocysteine-containing selenoproteins have so far been observed in human cells and tissues. Since lack of selenium deprives the cell of its ability to synthesize selenoproteins, many health effects of low selenium intake are believed to be caused by the lack of one or more specific selenoproteins. Three selenoproteins, TXNRD1 (TR1), TXNRD2 (TR3) and glutathione peroxidase 4 (GPX4), have been shown to be essential in mouse knockout experiments. On the other hand, too much dietary selenium causes toxic effects and can lead to selenium poisoning. The threshold between essential and toxic concentrations of this element is rather narrow with a factor in the range of 10-100. Mutations in Selenoprotein N (SELENON, formerly SEPN1) in humans cause a subtype of congenital muscular dystrophy known as SELENON-related myopathy.
The recreational use of ether also took place at organised parties in the 19th century called ether frolics, where guests were encouraged to inhale therapeutic amounts of diethyl ether or nitrous oxide, producing a state of excitation. Long, as well as fellow dentists Horace Wells, William Edward Clarke, and William T. G. Morton, observed that during these gatherings, people would often experience minor injuries but appear to show no reaction to them, nor memory that it had happened, demonstrating ether's anaesthetic effects. In the 19th and early 20th centuries, ether drinking was popular among Polish peasants. It is a traditional and still relatively popular recreational drug among Lemkos. It is usually consumed in a small quantity (kropka, or "dot") poured over milk, sugar water, or orange juice in a shot glass. As a drug, it has been known to cause psychological dependence, sometimes referred to as etheromania. Ether intoxication is referenced in Hunter S. Thompson's Fear and Loathing in Las Vegas, where in one of the book's most famous quotes, protagonist Raoul Duke declares that "There is nothing in the world more helpless and irresponsible and depraved than a man in the depths of an ether binge."
The term "isotope", Greek for "at the same place", was suggested to Soddy by Margaret Todd, a Scottish physician and family friend, during a conversation in which he explained his ideas to her. He received the 1921 Nobel Prize in Chemistry in part for his work on isotopes.
Most UPS Ground vehicles have no air conditioning, with the exception of tractor-trailers. This has been considered to be a contributing factor to heatstroke and other heat-related health problems in drivers who work in these vehicles for the entire shift. Modern vehicles have improved ventilation systems. On January 29, 2020, UPS invested in Arrival and ordered 10,000 Generation 2 Electric Vehicles.
Sources: en.wikipedia.org
Liquid chromatography–mass spectrometry is commonly used. It provides molecular mass and purity information. Other methods may include HPLC with ultraviolet detection.
Dihexa is often described as an HGF mimetic that activates c-Met signaling. Some research also links it to angiotensin IV pathways. The precise targets and human relevance remain uncertain.
The powder is typically stored at -20 °C, desiccated and protected from light. Avoid repeated freeze-thaw cycles. Follow supplier instructions and institutional guidelines.
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.